Ryan H. Saadi Increases Stake in Tevogen Bio Holdings Inc. to 59.7% via Restricted Stock Grant

On July 14, 2026, Ryan H. Saadi, the Chairman and Chief Executive Officer of Tevogen Bio Holdings Inc. (TVGN), filed an amendment to his Schedule 13D reporting an increase in his beneficial ownership. The change was primarily driven by a grant of 1,220,000 shares of Restricted Stock received on July 10, 2026, as compensation for his executive services. These restricted shares vest in four equal annual installments starting on the seventh anniversary of the grant date, though they carry immediate voting rights. Following this transaction, Dr. Saadi beneficially owns a total of 3,709,567 shares, representing approximately 59.7% of the company's outstanding common stock. This total includes 1,766,979 shares of restricted stock with voting rights and 3,878 shares held by his spouse. The filing confirms that Dr. Saadi maintains significant control over the issuer, holding sole voting power over 3,705,689 shares and shared power over his spouse's holdings. This Amendment No. 3 updates previous disclosures from February 2024, July 2025, and December 2015.